Publications by authors named "Shanshan Suo"

Claim this Profile
L
Long-term Efficacy and Safety of Ropeginterferon Alfa-2b under its HIDAT Regimen for the Treatment of Polycythemia Vera.
Shanshan Suo, Rongfeng Feng Fu, Albert Qin, Zonghong Shao, Jie Bai

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia.
Bingqian Jiang, Hongyan Tong, Min Yang, Huafeng Wang, Shanshan Suo

Blood Cancer J· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera.
Albert Qin, Kazuya Shimoda, Shanshan Suo, Rongfeng Fu, Keita Kirito

Pharmacol Res Perspect· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of subcutaneous injection versus intravenous infusion of cytarabine for induction therapy in adult acute myeloid leukemia.
Huafeng Wang, Shanshan Suo, Dengju Li, Jianyong Li, Lu Liu

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: Bench and bed.
Shanshan Suo, Shu Sun, Le Xuan Truong Nguyen, Jiejing Qian, Fenglin Li

Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b.
Shanshan Suo, Rong Feng Fu, Albert Qin, Zonghong Shao, Jie Bai

Br J Haematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study.
Yi Zhang, Hu Zhou, Shanshan Suo, Junling Zhuang, Linhua Yang

Blood Cancer J· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia.
Shanshan Suo, Dandan Zhao, Fenglin Li, Yi Zhang, Sonia Rodriguez-Rodriguez

Blood· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MN1::ETV6-positive de novo T-cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report.
Xiang Zhang, Yi Zhong, Lixia Liu, Shanshan Suo, Shuqi Zhao

Br J Haematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia.
Keita Kirito, Albert Qin, Shanshan Suo, Rongfeng Fu, Daoxiang Wu

BJC Rep· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Shanshan Suo

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteolytic lesion as initial presentation in FIP1L1-PDGFRA-rearranged myeloid/lymphoid neoplasm with eosinophilia: a case report.
Yunfei Lv, XingYun Yao, Qing Ling, Shanshan Suo, Jinghan Wang

Ann Hematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
Yi Zhang, Qike Zhang, Qingchi Liu, Huibing Dang, Sujun Gao, Shanshan Suo

Am J Hematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
Yi Zhang, Hu Zhou, Minghui Duan, Sujun Gao, Guangsheng He, Shanshan Suo

Am J Hematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spred1 deficit promotes treatment resistance and transformation of chronic phase CML.
Junjing Qiao, Chen Liang, Dandan Zhao, Le Xuan Truong Nguyen, Fang Chen, Shanshan Suo

Leukemia· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of chemotherapy-induced diabetes mellitus in acute lymphoblastic leukemia patients.
Shan-Shan Suo, Chen-Ying Li, Yi Zhang, Jing-Han Wang, Yin-Jun Lou

J Zhejiang Univ Sci B· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IDH1 -mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC.
Xiang Zhang, Shanshan Suo, Jinghan Wang, Jie Jin, Wenjuan Yu

Br J Haematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study.
Yi Zhang, Shan-Shan Suo, Han-Jin Yang, Xin-Ping Zhou, Liang-Shun You

J Cancer Res Clin Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miR-221-3p Delivered by BMMSC-Derived Microvesicles Promotes the Development of Acute Myelocytic Leukemia.
Xuewu Zhang, Yu Xu, Jinghan Wang, Shuqi Zhao, Jianhu Li, Shanshan Suo

Front Bioeng Biotechnol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-rearrangements resemble acute promyelocytic leukemia and benefit from 3 + 7 regimen.
Xiang Zhang, Fenglin Li, Jinghan Wang, Shanshan Suo, Qing Ling

Leuk Lymphoma· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of hypoxia-inducible factor-1a predicts benefit from rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.
Jie Jin, Lihong Cao, Lijun Wang, Zhaoming Wang, Wei Ding, Shanshan Suo

Int J Clin Exp Pathol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy.
Yinjun Lou, Ying Lu, Zhijuan Zhu, Yafang Ma, Shanshan Suo

Hematol Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells.
Jian Chen, Qitian Mu, Xia Li, Xiufeng Yin, Mengxia Yu, Shanshan Suo

Oncotarget· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypofibrinogenemia as a clue in the presumptive diagnosis of acute promyelocytic leukemia.
Yinjun Lou, Shanshan Suo, Hongyan Tong, Wenbin Qian, Wenyuan Mai

Leuk Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia].
Cuihua Fan, Wenjuan Yu, Wenyuan Mai, Haitao Meng, Wenbin Qian, Shanshan Suo

Zhonghua Xue Ye Xue Za Zhi· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis